Investor Presentation First Nine Months of 2023
8
Investor presentation
First nine months of 2023
GLP-1 class expansion continues in the US in the first nine
months of 2023
US GLP-1 weekly NBRx prescriptions
Weekly NBRX
scripts ('000s)
00
90
60
60
30
0
Oct
2021
Ozempic Rybelsus®
Novo NordiskⓇ
US GLP-1 TRX market share
TRX share
Total GLP-1 scripts
(millions)
Class growth ~50%
80%
7
6
60%
53.1% 5
42.3%
4
40%
3
26.6%
19.5% 2
20%
7.2%
1
3.7%
0%
0
Oct
Oct
Oct
2023
2021
2023
VictozaⓇ
NN GLP-1
-
dulaglutide tirzepatide
Total monthly GLP-1 scripts
NBRX: New-to-brand prescriptions; TRx: Total prescriptions; NN: Novo Nordisk; Scripts: Prescriptions; US: United States
Note: Class growth calculated as Q3 2023 vs Q3 2022
Source: IQVIA Xponent, NBRx data from week ending 13 Oct 2023. TRX data from week ending 13 Oct 2023. Each data points represents a rolling four-week averageView entire presentation